NCT03915470: Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection |
|
|
| Completed | 2 | 124 | US, RoW | XF-73, Exeporfinium chloride, Placebo, Matched Placebo | Destiny Pharma Plc | Staphylococcal Infections, Surgical Site Infection | 01/21 | 03/21 | | |
NCT02282605: Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects |
|
|
| Completed | 1/2 | 60 | Europe | XF-73 nasal gel, Placebo nasal gel, Chlorhexidine gluconate 2% topical cloths | Destiny Pharma Plc | Staphylococcus Aureus Infection | 11/14 | 11/14 | | |
